Benzinga | Jul 29, 2021 12:15PM EDT

Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $185 to $160.